MedTrace Logo

A Clinical Trial of Two Adjuvant Chemotherapy Regimens for Postoperative Gastric Cancer

NCT04351867 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 196

Last updated 2020-07-16

No results posted yet for this study

Summary

This study was a prospective, randomized, controlled phase III clinical study to evaluate the efficacy and safety of docetaxel plus oxaliplatin and capecitabine versus oxaliplatin plus capecitabine in the treatment of gastric or gastroesophageal junction adenocarcinoma with postoperative pathological stage IIIB and IIIC.

Conditions

  • Stomach Neoplasms

Interventions

DRUG

docetaxel plus oxaliplatin and capecitabine

docetaxel 50mg/㎡ ivgtt. d1+oxaliplatin 100mg/㎡ ivgtt. d1+capecitabine 1000mg/㎡ bid p.o. d1-d14 q21d

DRUG

oxaliplatin plus capecitabine

oxaliplatin 130mg/㎡ ivgtt. d1+capecitabine 1000mg/㎡ bid p.o. d1-d14 q21d

Sponsors & Collaborators

  • LiNing

    lead OTHER_GOV

Principal Investigators

  • Ning Li, PhD · Henan Cancer Hospital

  • Suxia Luo, PhD · Henan Cancer Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-30
Primary Completion
2024-06-30
Completion
2024-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04351867 on ClinicalTrials.gov